Skip to main content
Premium Trial:

Request an Annual Quote

MetriGenix Acquires GeneXP to Pool Gene Expression-Based Biomarker Efforts

NEW YORK, June 7 (GenomeWeb News) - MetriGenix of Toronto has acquired GeneXP Biosciences of Woburn, Mass., MetriGenix said today.


Financial and other terms of the acquisition were not disclosed.


Both companies have been developing gene expression-based biomarkers for different diseases using microarray technology. The acquisition will compbine their biomarker development activities "into a single portfolio that can be managed and developed faster and more efficiently," said Michael Cohen, the former president of GeneXP and new CEO of MetriGenix, in a company statement.


The combined company will continue to operate in Torontoand Woburn.

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.